BioAtla to Participate in the Jefferies Global Healthcare Conference
BioAtla (Nasdaq: BCAB), a clinical-stage biotech firm specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced its participation in the Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
The event will feature a fireside chat and one-on-one investor meetings on June 5, 2024, at 8:00 a.m. ET. The webcast will be available for interested parties.
- BioAtla's participation in a renowned conference can increase visibility and attract potential investors.
- Engagements like fireside chats and one-on-one meetings offer opportunities for direct investor communication, potentially boosting investor confidence.
- No new clinical or financial data announced, which may disappoint investors looking for concrete updates.
- Participation in conferences entails costs and resource allocation that may not yield immediate financial returns.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.
Format: Fireside chat and scheduled one-on-one investor meetings
Date: Wednesday, June 5, 2024
Time: 8:00 a.m. ET
Location: New York, NY
Webcast Link: Click Here
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 485 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What event is BioAtla (BCAB) participating in?
When is BioAtla's fireside chat at the Jefferies Global Healthcare Conference?
Where is the Jefferies Global Healthcare Conference held?
What is the ticker symbol for BioAtla?
What will BioAtla discuss at the Jefferies Global Healthcare Conference?
